Lebl J, Zemková D, Kolousková S, Snajderová M
2. dĕtská klinika 2. LF UK a Fakultní nemocnice v Praze-Motole.
Cas Lek Cesk. 1994 Apr 18;133(8):237-41.
Despite different age, stature, severity of hormone deficiency and target height children with growth hormone deficiency are usually given a uniform therapeutic dose of the preparation. Knowledge of the basic variables which influence individual therapeutic effects of growth hormone would make it possible to elaborate for individual patients a specific therapeutic strategy with the aim to cath up with the deficiency in height at an appropriate calendar age.
The authors treated for a period of one year, using three different dosages of growth hormone, 25 prepubertal children with growth hormone deficiency (post-stimulation level < 8 mIU/l). Group A (9 children aged 11.2 +/- 2.0 years) were treated with 0.42 IU/kg/week, group B (7 children, aged 11.4 +/- 4.6 years) 0.7 IU/kg/week and group C (9 children, aged 10.2 +/- 2.4 years) 1.0 IU/kg/week. The preparation was administered daily before bedtime by the s.c. route. The growth rate during treatment increased from (mean +/- SD) 2.6 +/- 0.9 to 9.3 +/- 1.5 cm/year (group A), from 2.3 +/- 1.0 to 10.4 +/- 2.5 cm/year (group B) and from 3.1 +/- 0.7 to 12.6 +/- 1.9 cm/year (group C, p < 0.05 as compared with group A). The height age increased per year of treatment significantly more in children of group C (by 2.1 +/- 0.3 year) than in group A (by 1.6 +/- 0.3 year) or in group B (by 1.7 +/- 0.3 year). No difference was found between the groups in the ratio of changes in height and bone age. From 10 analyzed variables the growth rate during treatment is predicted above all by the therapeutic dose (r = 0.60), and to a lesser extent by the target height (r = 0.53).
The therapeutic dose is the decisive parameter for prediction of the therapeutic effect of growth hormone in children with growth hormone deficiency. It is justified to modify the therapeutic dose individually with regard to the initial characteristic and therapeutic target of every given patient.
尽管生长激素缺乏症患儿年龄、身高、激素缺乏严重程度及靶身高各不相同,但通常给予统一的治疗剂量。了解影响生长激素个体治疗效果的基本变量,将有助于为个体患者制定特定的治疗策略,以期在适当的实际年龄弥补身高缺陷。
作者用三种不同剂量的生长激素对25名青春期前生长激素缺乏症患儿(刺激后水平<8 mIU/l)进行了为期一年的治疗。A组(9名儿童,年龄11.2±2.0岁)接受0.42 IU/kg/周的治疗,B组(7名儿童,年龄11.4±4.6岁)接受0.7 IU/kg/周的治疗,C组(9名儿童,年龄10.2±2.4岁)接受1.0 IU/kg/周的治疗。药物通过皮下途径每天睡前给药。治疗期间的生长速度从(均值±标准差)2.6±0.9厘米/年增加到9.3±1.5厘米/年(A组),从2.3±1.0厘米/年增加到10.4±2.5厘米/年(B组),从3.1±0.7厘米/年增加到12.6±1.9厘米/年(C组,与A组相比p<0.05)。C组患儿治疗每年身高年龄增加(2.1±0.3岁)明显多于A组(1.6±0.3岁)或B组(1.7±0.3岁)。各组身高变化与骨龄变化的比值无差异。在分析的10个变量中,治疗期间的生长速度首先由治疗剂量预测(r = 0.60),其次由靶身高预测(r = 0.53)。
治疗剂量是预测生长激素缺乏症患儿生长激素治疗效果的决定性参数。根据每个特定患者的初始特征和治疗目标个体化调整治疗剂量是合理的。